Objective: To assess the feasibility and acceptability of randomizing the phased introduction of the extension of the invited age range in the National Health Service (NHS) Breast Screening Programme in England from 50-70 to 47-73 years.
Setting: Six volunteer breast screening units (BSUs) in England.
Methods: Cluster-randomized trial of invitation versus no invitation for breast screening.
Study Participants: women aged 47-49 and 71-73 years in screening batches randomized between 1 June 2009 and 31 May 2010.
Outcomes: workload, screening uptake among women invited, self-referrals among women not invited, and screening outcomes among women invited.
Results: A total of 312 screening batches (clusters) were randomized including 60,708 women. Screening uptake was 63% in women aged 47-49 and 62% in women aged 71-73. Those who attended screening in the younger age group were more likely to be recalled for assessment than older attendees (7.5% vs. 3.0%) but less likely to be diagnosed with breast cancer (0.5% vs. 1.1%). Among women not invited, 0.2% of those aged 47-49 and 6.8% of those aged 71-73 self-referred for screening. Despite the extra workload BSUs largely coped although there was some slippage in round lengths and other targets.
Conclusion: No major problems of feasibility or acceptability of randomization were found. This pilot study has informed the randomized phasing-in of the age extension across the whole of England.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1258/jms.2011.011065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of immune-checkpoint LAG3 as a biomarker finding tool in patient-derived organoid cultures of breast cancer.
Sci Rep
December 2024
IRCCS SYNLAB SDN, Naples, 80143, Italy.
LAG3 plays a regulatory role in immunity and emerged as an inhibitory immune checkpoint molecule comparable to PD-L1 and CTLA-4 and a potential target for enhancing anti-cancer immune responses. We generated 3D cancer cultures as a model to identify novel molecular biomarkers for the selection of patients suitable for α-LAG3 treatment and simultaneously the possibility to perform an early diagnosis due to its higher presence in breast cancer, also to achieve a theragnostic approach. Our data confirm the extreme dysregulation of LAG3 in breast cancer with significantly higher expression in tumor tissue specimens, compared to non-cancerous tissue controls.
View Article and Find Full Text PDFDeep learning radiomics on grayscale ultrasound images assists in diagnosing benign and malignant of BI-RADS 4 lesions.
Sci Rep
December 2024
Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, No. 16766, Jingshi Road, Jinan, 250014, Shandong, People's Republic of China.
This study aimed to explore a deep learning radiomics (DLR) model based on grayscale ultrasound images to assist radiologists in distinguishing between benign breast lesions (BBL) and malignant breast lesions (MBL). A total of 382 patients with breast lesions were included, comprising 183 benign lesions and 199 malignant lesions that were collected and confirmed through clinical pathology or biopsy. The enrolled patients were randomly allocated into two groups: a training cohort and an independent test cohort, maintaining a ratio of 7:3.
View Article and Find Full Text PDFIdentification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer.
Sci Rep
December 2024
Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Breast cancer is a leading cause of cancer-related deaths among women globally. It is imperative to explore novel biomarkers to predict breast cancer treatment response as well as progression. Here, we collected six breast cancer samples and paired normal tissues for high-throughput sequencing.
View Article and Find Full Text PDFThe Gift of Time, How Do I Want to Spend It? Exploring Preferences for Time Allocation Among Women with and without a Breast Cancer Diagnosis.
Appl Health Econ Health Policy
December 2024
Health Systems and Health Economics, School of Public Health, Curtin University, Bentley, Perth, Australia.
Background: Women's preferences for time allocation reveal how they would like to prioritise market work, family life, and other competing activities. Whilst preferences may not always directly translate to behaviour, they are an important determinant of intention to act.
Objective: We present the first study to apply a discrete choice experiment (DCE) to investigate time allocation preferences among women diagnosed with breast cancer and women without a cancer diagnosis.
Self-assembled natural triterpenoids for the delivery of cyclin-dependent kinase 4/6 inhibitors to enhance cancer chemoimmunotherapy.
J Control Release
December 2024
Key Laboratory of Natural Medicine Innovation and Transformation, Henan University, Kaifeng 475000, PR China; State Key Laboratory of Antiviral Drugs, Henan University, Kaifeng 475000, PR China; Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, PR China. Electronic address:
Immunogenic cell death (ICD) has recently emerged as a promising strategy in reinforcing anti-PD-L1 blockade immunotherapy of triple-negative breast cancer (TNBC). The CDK4/6 inhibitor palbociclib (PAL), as a clinical star medicine targeting the cell cycle machinery, is an ideal candidate for fabricating a highly efficient ICD inducer for TNBC chemoimmunotherapy. However, the frequently observed chemoresistance and clinical adverse effects, as well as significant antagonistic effects when co-administered with certain chemotherapeutics, have seriously restricted the efficiency of PAL and the feasibility of combination strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!